|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
179,400,000 |
Market
Cap: |
227.84(M) |
Last
Volume: |
2,211,986 |
Avg
Vol: |
2,301,679 |
52
Week Range: |
$0.449 - $1.83 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for cancer and autoimmune disease. Co.'s proprietary programs include: Immuno-oncology, which involves in developing medicines that target biological pathways which stimulate and sustain the body's immune response in order to fight cancer; and Pain, NKTR-181, a mu-opioid analgesic drug candidate patients with chronic low back pain. Co.'s NKTR-358 is an investigational drug designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
86,265 |
122,918 |
235,260 |
541,068 |
Total Sell Value |
$152,594 |
$177,518 |
$247,417 |
$1,284,611 |
Total People Sold |
4 |
4 |
7 |
10 |
Total Sell Transactions |
4 |
7 |
16 |
37 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Chess Robert |
Director |
|
2021-08-24 |
4 |
GA |
$0.00 |
$0 |
I/I |
6,300 |
2,100 |
|
- |
|
Chess Robert |
Director |
|
2021-08-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
6,300 |
274,273 |
|
- |
|
Labrucherie Gil M |
SVP, COO & CFO |
|
2021-08-17 |
4 |
AS |
$13.56 |
$40,680 |
D/D |
(3,000) |
240,231 |
|
10% |
|
Labrucherie Gil M |
SVP, COO & CFO |
|
2021-08-16 |
4 |
AS |
$13.83 |
$108,801 |
D/D |
(7,867) |
243,231 |
|
12% |
|
Zalevsky Jonathan |
Chief R&D Officer |
|
2021-08-16 |
4 |
S |
$13.83 |
$105,965 |
D/D |
(7,662) |
212,803 |
|
-12% |
|
Northcott John |
SVP & Chief Commercial Officer |
|
2021-08-16 |
4 |
S |
$13.83 |
$85,635 |
D/D |
(6,192) |
200,915 |
|
-12% |
|
Wilson Mark Andrew |
SVP & General Counsel |
|
2021-08-16 |
4 |
S |
$13.83 |
$26,415 |
D/D |
(1,910) |
72,900 |
|
-12% |
|
Thomsen Jillian B. |
SVP & Chief Accounting Officer |
|
2021-08-16 |
4 |
S |
$13.83 |
$184,478 |
D/D |
(13,339) |
137,822 |
|
-12% |
|
Robin Howard W |
President & CEO |
|
2021-08-16 |
4 |
S |
$13.83 |
$159,252 |
D/D |
(11,515) |
424,123 |
|
-12% |
|
Chess Robert |
Director |
|
2021-07-22 |
4 |
AS |
$16.80 |
$1,529 |
D/D |
(91) |
280,573 |
|
-32% |
|
Chess Robert |
Director |
|
2021-07-22 |
4 |
OE |
$13.80 |
$1,256 |
D/D |
91 |
280,664 |
|
- |
|
Chess Robert |
Director |
|
2021-07-21 |
4 |
AS |
$16.81 |
$59,238 |
D/D |
(3,524) |
280,573 |
|
-33% |
|
Chess Robert |
Director |
|
2021-07-21 |
4 |
OE |
$13.80 |
$48,631 |
D/D |
3,524 |
284,097 |
|
- |
|
Chess Robert |
Director |
|
2021-07-20 |
4 |
AS |
$16.80 |
$35,381 |
D/D |
(2,106) |
280,573 |
|
-31% |
|
Chess Robert |
Director |
|
2021-07-20 |
4 |
OE |
$13.80 |
$29,063 |
D/D |
2,106 |
282,679 |
|
- |
|
Wilson Mark Andrew |
SVP & General Counsel |
|
2021-05-17 |
4 |
S |
$18.30 |
$35,081 |
D/D |
(1,917) |
74,810 |
|
-2% |
|
Labrucherie Gil M |
SVP, COO & CFO |
|
2021-05-17 |
4 |
S |
$18.30 |
$144,533 |
D/D |
(7,898) |
251,098 |
|
-2% |
|
Robin Howard W |
President & CEO |
|
2021-05-17 |
4 |
S |
$18.30 |
$211,548 |
D/D |
(11,560) |
435,638 |
|
-2% |
|
Northcott John |
SVP & Chief Commercial Officer |
|
2021-05-17 |
4 |
S |
$18.30 |
$111,356 |
D/D |
(6,085) |
207,107 |
|
-2% |
|
Thomsen Jillian B. |
SVP & Chief Accounting Officer |
|
2021-05-17 |
4 |
S |
$18.30 |
$245,055 |
D/D |
(13,391) |
151,161 |
|
-2% |
|
Zalevsky Jonathan |
Chief R&D Officer |
|
2021-05-17 |
4 |
S |
$18.30 |
$569,331 |
D/D |
(31,111) |
235,065 |
|
-2% |
|
Chess Robert |
Director |
|
2021-05-12 |
4 |
AS |
$19.34 |
$154,720 |
D/D |
(8,000) |
280,573 |
|
-5% |
|
Chess Robert |
Director |
|
2021-05-12 |
4 |
OE |
$13.80 |
$110,400 |
D/D |
8,000 |
288,573 |
|
- |
|
Chess Robert |
Director |
|
2021-04-14 |
4 |
AS |
$18.98 |
$151,840 |
D/D |
(8,000) |
280,573 |
|
-27% |
|
Chess Robert |
Director |
|
2021-04-14 |
4 |
OE |
$13.80 |
$110,400 |
D/D |
8,000 |
288,573 |
|
- |
|
913 Records found
|
|
Page 5 of 37 |
|
|